Regeneron Pharmaceuticals REGN Property, plant and equipment, net
Property, plant and equipment, net at other companies
Segments
By geography
See fullOther financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's property, plant and equipment, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's property, plant and equipment, net?
- Regeneron Pharmaceuticals (REGN) reported property, plant and equipment, net of $5.27B in Q1 2026.
- How has Regeneron Pharmaceuticals's property, plant and equipment, net changed year-over-year?
- Regeneron Pharmaceuticals's property, plant and equipment, net increased by 12.2% year-over-year, from $4.69B to $5.27B.
- What is the long-term trend for Regeneron Pharmaceuticals's property, plant and equipment, net?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's property, plant and equipment, net has grown at a 9.7% compound annual growth rate (CAGR), from $3.22B to $5.12B.
- What does property, plant and equipment, net mean?
- The net value of long-term physical assets like buildings, labs, and manufacturing equipment.
- How do you interpret property, plant and equipment, net?
- Growth in this metric indicates ongoing capital investment in production capacity or research infrastructure.
- How does property, plant and equipment, net compare across companies?
- High for manufacturing-heavy industries; pharmaceutical companies require significant investment in specialized production facilities.